Revenue growth is accelerating (73% YoY) and the company is now GAAP-profitable. Watch for ASCO data readouts (May 29-June 2) and continued sales execution in AYA expansion. The cash runway is solid through current operating plan. The EPS beat is small in absolute terms but confirms the revenue trajectory.
Price Chart
Executive Summary
Fennec Pharmaceuticals reported Q1 2026 revenue of $15.1M (+73% YoY) and GAAP net income of $0.01 per diluted share, versus consensus estimates of $13.8M revenue and a $-0.02 EPS loss. The EPS beat is driven by GAAP profitability on lower operating expenses, but the company is a pre-commercial-stage biotech with minuscule absolute EPS, making the surprise a mechanical artifact. Revenue growth is strong and accelerating, supported by record PEDMARK demand in April and expanding clinical interest.
Key Financial Metrics
Key Facts
- Q1 2026 net product sales of $15.1M, up 73% YoY from $8.8M
- GAAP net income of $0.01 per diluted share vs consensus $-0.02 loss
- Record PEDMARK demand in April 2026, with field sales expansion showing early positive results
- Cash and equivalents of $40.1M, up from $36.8M at year-end 2025
- Four PEDMARK abstracts accepted at 2026 ASCO Annual Meeting (May 29-June 2)
- Third institution-led clinical study initiated in AYA and adult head/neck and testicular cancers
- Operating cash flow of ~$2.3M in Q1; total operating expenses $15.2M vs $9.6M YoY
Financial Impact
Revenue beat of ~$1.3M vs consensus ($15.1M actual vs $13.8M est); GAAP EPS surprise of +$0.03 vs consensus -$0.02
Risk Factors
- Dependence on single product PEDMARK for all revenue
- Selling and marketing expenses nearly tripled YoY to $11.4M, pressuring margins
- Clinical expansion into adult populations is early-stage and unproven
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294695 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.30 (+0.29%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.30 (−19.41%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.30 (+12.08%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.30 (+4.15%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.30 (+5.53%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.30 (+11.47%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.30 (+49.28%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.30 (+64.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers